* patients under treatment with n-acetylcysteine or sartan. * patients with a dysimmune pathology or immunosuppressive treatment. * person infected with sars-cov-2 within 3 months prior to inclusion. * person participating in a category 1 defined riph. * subject in an exclusion period as determined by another study. * person under court protection, guardianship or trusteeship. * subject who is unable to give consent. * subject for whom it is impossible to give clear information. * pregnant or breastfeeding woman.

* patients under treatment with n-acetylcysteine or sartan. * patients with a dysimmune pathology or immunosuppressive treatment. * person infected with sars-cov-2 within 3 months prior to inclusion. * person participating in a category 1 defined riph. * subject in an exclusion period as determined by another study. * person under court protection, guardianship or trusteeship. * subject who is unable to give consent. * subject for whom it is impossible to give clear information. * pregnant or breastfeeding woman.

patients under treatment with n-acetylcysteine or sartan. patients with a dysimmune pathology or immunosuppressive treatment. person infected with sars-cov-2 within 3 months prior to inclusion. person participating in a category 1 defined riph. subject in an exclusion period as determined by another study. person under court protection, guardianship or trusteeship. subject who is unable to give consent. subject for whom it is impossible to give clear information. pregnant or breastfeeding woman.

patients under treatment with n-acetylcysteine or sartan. patients with a dysimmune pathology or immunosuppressive treatment. person infected with sars-cov-2 within 3 months prior to inclusion. person participating in a category 1 defined riph. subject in an exclusion period as determined by another study. person under court protection, guardianship or trusteeship. subject who is unable to give consent. subject for whom it is impossible to give clear information. pregnant or breastfeeding woman.